핵의학/방사성의약품 시장 규모 : 용도별, 시술 수별, 유형별, 지역별, 범위 및 예측

Nuclear Medicine/Radiopharmaceuticals Market Size And Forecast

Nuclear Medicine/Radiopharmaceuticals Market size was valued at USD 6.56 Billion in 2020 and is projected to reachUSD 13.53 Billion by 2028, growing at aCAGR of 9.47% from 2021 to 2028.

The demand for radiopharmaceuticals in neurological applications will drive the growth of the Nuclear Medicine/Radiopharmaceuticals Market during the forecast period. The Global Nuclear Medicine/Radiopharmaceuticals Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Nuclear Medicine/Radiopharmaceuticals Market Definition

The radioactive compounds administered to the patient and monitored via a specific imaging device for diagnostic purposes are known as radiopharmaceuticals. This drug can be used for therapeutic or diagnostic purposes. The radiopharmaceuticals are mainly composed of a radioisotope bond to an organic molecule. Over the last 50 years, nuclear medicine has developed significantly owing to increasing investments in the field of chemistry and the development of radionuclides and radiolabeled compounds.

Global Nuclear Medicine/Radiopharmaceuticals Market Overview

The growth of the global Nuclear Medicine/Radiopharmaceuticals Market is being driven by increasing incidences and prevalence of target conditions. The demand for alpha radioimmunotherapy-based targeted cancer treatment is increasing and owing to which the global Nuclear Medicine/Radiopharmaceuticals Market is flourishing at a rapid pace.

However, some restraints are liming the growth of the global Nuclear Medicine/Radiopharmaceuticals Market. The short life span of radiopharmaceuticals may create setbacks for the growth of the global Nuclear Medicine/Radiopharmaceuticals Market. Also, the high equipment prices may hamper the growth of the global Nuclear Medicine/Radiopharmaceuticals Market.

Global Nuclear Medicine/Radiopharmaceuticals Market: Segmentation Analysis

The Global Nuclear Medicine/Radiopharmaceuticals Market is Segmented on the basis of Application, Procedural Volume, Type, and Geography.

Nuclear Medicine/Radiopharmaceuticals Market, By Application

• 1.1 Diagnostic Applications
  • 1.1.1 SPECT Applications
  • 1.1.1.1 Cardiology
  • 1.1.1.2 Neurology
  • 1.1.1.3 Thyroid
• 1.2 Other SPECT Applications
  • 1.2.1 PET Applications
  • 1.2.1.1 Oncology
  • 1.2.1.2 Cardiology
  • 1.2.1.3 Neurology
  • 1.2.1.4 Other PET Applications
  • 1.2.2 Therapeutic Applications
  • 1.2.3 Thyroid
  • 1.2.4 Bone Metastasis
  • 1.2.5 Lymphoma
  • 1.2.6 Endocrine Tumors
  • 1.2.7 Other Therapeutic Applications

Based on Application, the market is segmented into Diagnostic Applications and Other SPECT Applications. The diagnostic applications dominated the global Nuclear Medicine/Radiopharmaceuticals Market. The SPECT applications especially contributed majorly to the growth of the market.

Nuclear Medicine/Radiopharmaceuticals Market, By Procedural Volume

• 2.1 Diagnostic Procedures
  • 2.1.1 SPECT Radiopharmaceuticals
  • 2.1.2 PET Radiopharmaceuticals
• 2.2 Therapeutic Procedures
  • 2.2.1 Beta Emitters
  • 2.2.2 Alpha Emitters
  • 2.2.3 Brachytherapy Isotopes

Based on Procedural Volume, the market is segmented into Diagnostic Procedures and Therapeutic Procedures. The Diagnostic Procedures are further bifurcated into SPECT Radiopharmaceuticals, PET Radiopharmaceuticals, and Therapeutic Procedures. The Therapeutic Procedures are further bifurcated into Beta Emitters, Alpha Emitters, and Brachytherapy Isotopes. The Diagnostic Procedures dominated the global Nuclear Medicine/Radiopharmaceuticals Market.

Nuclear Medicine/Radiopharmaceuticals Market, By Type

• 3.1 Diagnostic Nuclear Medicine
  • 3.1.1 SPECT Radiopharmaceuticals
  • 3.1.1.1 Tc-99m
  • 3.1.1.2 Tl-201
  • 3.1.1.3 Ga-67
  • 3.1.1.4 I-123
  • 3.1.1.5 Other SPECT Isotopes
• 3.3 PET Radiopharmaceuticals
  • 3.2.1 F-18
  • 3.2.2 Rubidium-82
  • 3.2.3 Other PET Isotopes
• 3.3 Therapeutic Nuclear Medicine/Radiopharmaceuticals
  • 3.3.1 Beta Emitters
  • 3.3.1.1 Iodine-131
  • 3.3.1.2 Y-90
  • 3.3.1.3 Sm-153
  • 3.3.1.4 Re-186
  • 3.3.1.5 Lu-177
  • 3.3.1.6 Other Beta Emitters
  • 3.3.2 Alpha Emitters
  • 3.3.2.1 Ra-223
  • 3.3.3 Brachytherapy Isotopes
  • 3.3.3.1 Iodine-125
  • 3.3.3.2 Iridium-192
  • 3.3.3.3 Palladium-103
  • 3.3.3.4 Cesium-131
  • 3.3.3.5 Other Brachytherapy Isotopes

Based on Type, the market is segmented into Diagnostic Nuclear Medicine, PET Radiopharmaceuticals, and Therapeutic Nuclear Medicine/Radiopharmaceuticals. The Therapeutic Nuclear Medicine/ Radiopharmaceuticals is further bifurcated into Beta Emitters, Alpha Emitters, and Brachytherapy Isotopes. The alpha emitters segment dominated the market.

Nuclear Medicine/Radiopharmaceuticals Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the world

Based on regional analysis, the Global Nuclear Medicine/Radiopharmaceuticals Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. The largest share in the market will be dominated by North America. The dominance of the North American region can be attributed to the development of novel technologies for radioscopic production and an increase in government funding.

Key Players

• The "Global Nuclear Medicine/Radiopharmaceuticals Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Cardinal Health, Inc., Mallinckrodt PLC, GE Healthcare (A Fully-Owned Subsidiary of General Electric Company), Lantheus Medical Imaging, Inc., Bayer AG, Bracco Imaging S.P.A, Eczacibasi-Monrol Nuclear Products, Nordion, Inc. (A Subsidiary of Sterigenics International LLC.), Advanced Accelerator Applications S.A., Iba Molecular.
• These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market.

Key Developments

• Partnerships, Collaborations and Agreements
• A manufacturing and distribution deal was signed in 2019 between Eczacba-Monrol and Telix Pharmaceuticals Limited (Australia). Telix has engaged Eczacba-Monrol as a radiopharmaceutical production partner and distributor throughout Turkey, the Middle East, and North Africa, according to the conditions of the agreement.
• Mergers and Acquisitions
• In the year 2019, Curium acquired MAP Medical, allowing it to expand its footprint in Europe and gain direct access to the Nordic and Baltic countries.
• Product Launches and Product Expansions
• Curium (France) and NRG (Netherlands) inked a Molybdenum-99 manufacturing agreement in 2019.
• Cobalt-60 was purchased from the Board of Radiation and Isotope Technology (BRIT) in April 2019 for distribution throughout Europe by Nordion, Inc.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY APPLICATION

• 5.1 Overview
• 5.2 Diagnostic Applications
  • 5.2.1 SPECT Applications
  • 5.2.1.1 Cardiology
  • 5.2.1.2 Neurology
  • 5.2.1.3 Thyroid
• 5.3 Other SPECT Applications
  • 5.3.1 PET Applications
  • 5.3.1.1 Oncology
  • 5.3.1.2 Cardiology
  • 5.3.1.3 Neurology
  • 5.3.1.4 Other PET Applications
  • 5.3.2 Therapeutic Applications
  • 5.3.3 Thyroid
  • 5.3.4 Bone Metastasis
  • 5.3.5 Lymphoma
  • 5.3.6 Endocrine Tumors
  • 5.3.7 Other Therapeutic Applications

6 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY PROCEDURAL VOLUME

• 6.1 Overview
• 6.2 Diagnostic Procedures
  • 6.2.1 SPECT Radiopharmaceuticals
  • 6.2.2 PET Radiopharmaceuticals
• 6.3 Therapeutic Procedures
  • 6.3.1 Beta Emitters
  • 6.3.2 Alpha Emitters
  • 6.3.3 Brachytherapy Isotopes

7 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY TYPE

• 7.1 Overview
• 7.2 Diagnostic Nuclear Medicine
  • 7.2.1 SPECT Radiopharmaceuticals
  • 7.2.1.1 Tc-99m
  • 7.2.1.2 Tl-201
  • 7.2.1.3 Ga-67
  • 7.2.1.4 I-123
  • 7.2.1.5 Other SPECT Isotopes
• 7.3 PET Radiopharmaceuticals
  • 7.3.1 F-18
  • 7.3.2 Rubidium-82
  • 7.3.3 Other PET Isotopes
• 7.4 Therapeutic Nuclear Medicine/ Radiopharmaceuticals
  • 7.4.1 Beta Emitters
  • 7.4.1.1 Iodine-131
  • 7.4.1.2 Y-90
  • 7.4.1.3 Sm-153
  • 7.4.1.4 Re-186
  • 7.4.1.5 Lu-177
  • 7.4.1.6 Other Beta Emitters
  • 7.4.2 Alpha Emitters
  • 7.4.2.1 Ra-223
  • 7.4.3 Brachytherapy Isotopes
  • 7.4.3.1 Iodine-125
  • 7.4.3.2 Iridium-192
  • 7.4.3.3 Palladium-103
  • 7.4.3.4 Cesium-131
  • 7.4.3.5 Other Brachytherapy Isotopes

8 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 EuropeRegional
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East & Africa

9 GLOBAL NUCLEAR MEDICINE/RADIOPHARMACEUTICALS MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 Cardinal Health, Inc.
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Mallinckrodt PLC
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 GE Healthcare (A Fully-Owned Subsidiary of General Electric Company)
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 Lantheus Medical Imaging, Inc.
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Bayer AG
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Bracco Imaging S.P.A
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Eczacibasi-Monrol Nuclear Products
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Nordion, Inc. (A Subsidiary of Sterigenics International LLC.)
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Advanced Accelerator Applications S.A.
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 Iba Molecular
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Reports